BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Nov 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
6/8 — Strong
Priority Review
RITUXAN (rituximab) by Roche is cd20-directed antibody interactions [moa]. Approved for diffuse large b-cell lymphoma, follicular lymphoma, non-hodgkin's lymphoma and 2 more indications. First approved in 1997.
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RITUXAN (rituximab) is a CD20-directed monoclonal antibody administered intravenously that works by targeting and eliminating B cells expressing the CD20 antigen. Originally approved by the FDA on November 26, 1997, it represents a foundational biologic therapy across multiple hematologic malignancies and autoimmune conditions. The drug functions as a cytolytic antibody, inducing B cell destruction through multiple mechanisms including antibody-dependent cellular cytotoxicity and direct induction of apoptosis. RITUXAN remains a standard-of-care agent in its approved indications despite being in the loss-of-exclusivity (LOE) approaching phase.
$0.0BPart D
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications (5)
Worked on RITUXAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.